Expresión nuclear del oncogén HER2 en cáncer epitelial de ovario

Héctor Marcelo Marín; Gustavo Emilio Giusiano; Luis Antonio Merino; María Alicia Cortés

doi:10.18004/mem.iics/1812-9528/2025.e23122506

Autores/as

Héctor Marcelo Marín Universidad Nacional del Nordeste, Facultad de Medicina. Corrientes, Argentina https://orcid.org/0000-0001-9259-8799
Gustavo Emilio Giusiano https://orcid.org/0000-0003-4696-4158
Luis Antonio Merino https://orcid.org/0000-0002-7525-3921
María Alicia Cortés https://orcid.org/0000-0001-7765-5302

DOI:

https://doi.org/10.18004/mem.iics/1812-9528/2025.e23122506

Palabras clave:

Oncogen, HER2, ovario, cáncer

Resumen

El oncogén HER2 ha sido implicado en la patogénesis del cáncer de ovario y puede servir como marcador pronóstico y diana terapéutica. En este estudio se analizó la expresión de HER2 en el núcleo celular de muestras de cáncer de ovario y tumores benignos, recolectadas en un hospital de Argentina entre 2021 y 2024, mediante inmunohistoquímica. Se encontró una expresión nuclear positiva de HER2 en el 26% de los casos (3+), 20% (2+), y el resto negativos. En contraste, la expresión en membrana citoplasmática fue escasa. Se observó una mayor frecuencia de HER2 nuclear en los tumores malignos comparados con los benignos (p<0.05). Estos resultados sugieren un posible rol de HER2 nuclear en la progresión tumoral y su valor potencial como biomarcador diagnóstico o pronóstico, aunque estas conclusiones iniciales deberán ser confirmadas con estudios posteriores.

Descargas

Los datos de descarga aún no están disponibles.

Referencias

1. Cai Y, Wang J, Zhao L, Wu D, Yu D, Tian X, et al. Expressions of fatty acid synthase and her2 are correlated with poor prognosis of ovarian cancer. Medical Oncology 2014; 32(1): 391.

2. Dewi I, Susraini A, Ekawati N. Her2/neu and ki-67 as prognostic factors in serous type ovarian carcinoma. Bali Medical Journal 2020; 9(2): 567-71.

3. Menderes G, Bonazzoli E, Bellone S, Altwerger G, Black J, Dugan K, et al. Superior in vitro and in vivo activity of trastuzumab-emtansine (t-dm1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high her2/neu expression. Gynecologic Oncology 2017; 147(1): 145-52.

4. Chen W, Bardhan R, Bartels M, Pérez-Torres C, Pautler R, Halas, et al. A molecularly targeted theranostic probe for ovarian cancer. Molecular Cancer Therapeutics 2010; 9(4): 1028-38.

5. Cordo Russo R, Chervo MF, Madera S, Charreau EH, Elizalde PV. Nuclear ErbB-2: a Novel Therapeutic Target in ErbB-2-Positive Breast Cancer?. Horm Cancer 2019; 10 (2):64-70.

6. Elizalde PV, Cordo Russo RI, Chervo MF, Schillaci R. ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy. Endocr Relat Cancer 2016; 23 (12):243-57.

7. Bi Y, Gong L, Liu P, Xiong X, Zhao Y. Nuclear ErbB2 represses DEPTOR transcription to inhibit autophagy in breast cancer cells. Cell Death Dis 2021; 12(4):397.

8. Madera S, Izzo F, Chervo MF, Dupont A, Chiauzzi VA, Bruni S, et al. Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer. Cell Death Dis 2022; 13(5):447.

9. Cong J, Liu R, Hou J, Wang X, Jiang H, Wang J. Effects of trastuzumab on the proliferation and apoptosis of ovarian cancer cells. Neoplasma 2019; 66(02): 240-4.

10. Mojtahedi Z, Erfani N, Malekzadeh M, Haghshenas M, Ghaderi A, Dehaghani A. Her2 ile655val single nucleotide polymorphism in patients with ovarian cancer. Iranian Red Crescent Medical Journal 2013; 15(1): 2173.

11. Wen W, Chen W, Xiao N, Bender R, Ghazalpour A, Tan Z, et al. Mutations in the kinase domain of the her2/erbb2 gene identified in a wide variety of human cancers. Journal of Molecular Diagnostics 2015; 17(5): 487-95.

12. Menderes G, Bonazzoli E, Bellone S, Black J, Lopez S, Pettinella et al. Efficacy of neratinib in the treatment of her2/neu-amplified epithelial ovarian carcinoma in vitro and in vivo. Medical Oncology 2017; 34(5): 91.

13. Corkery D, Page C, Meunier L, Provencher D, Mes-Masson A, Dellaire G. Prp4k is a her2-regulated modifier of taxane sensitivity. Cell Cycle 2015; 14(7): 1059-69.

14. Bellone MD, Mutlu L, McNamara B, Manavella DD, Demirkiran C, Verzosa MSZ, et al. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression. Gynecol Oncol. 2023; 170:38-45.

15. Juul CA, Engel TB, Fliedner FP, Ringgaard L, Eliasen R, Melander F, et al. HER2-targeted, enzyme-activated liposomes show superior in vivo efficacy in an ovarian cancer model. J Control Release 2024; 371:288-297.

16. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014; 138: 241-56.

17. Schillaci R, Guzmán P, Cayrol F, Beguelin W, Díaz Flaqué MC, Proietti CJ, et al. Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer. BMC Cancer. 2012; 12:74.

18. Han R, Madariaga A, Gonzalez-Ochoa E, Smith AC, Wang L, Lheureux S, et al. HER2-low and Overexpression in Mucinous Ovarian Cancer: Analysis of ASCO/CAP and ToGA Immunohistochemical Scoring. Int J Gynecol Pathol. 2024; 43(3):275-83.

19. Chung YW, Kim S, Hong JH, Lee JK, Lee NW, Lee YS, Song JY. Overexpression of HER2/HER3 and clinical feature of ovarian cancer. J Gynecol Oncol. 2019; 30(5): e75.

20. Boku N. HER2-positive gastric cancer. Gastric Cancer 2014, 17(1): 1-12.

21. Zhao X, Li Y, Zhang H, Cai Y, Wang X, Liu Y, Li T, Xu C, Teng Y, Li D, Li F. PAK5 promotes the trastuzumab resistance by increasing HER2 nuclear accumulation in HER2-positive breast cancer. Cell Death Dis 2025, 16(1):323.

22. Oh DY, Bang Y. HER2-targeted therapies - a role beyond breast cancer. Review Nat Rev Clin Oncol 2020, 17(1): 33-48.

23. Zhu K, Yang X, Tai H, Zhong X, Luo T, Zheng H. HER2-targeted therapies in cancer: a systematic review. Biomark Res 2024, 12(1):16.

24. Cheng X. A Comprehensive Review of HER2 in Cancer Biology and Therapeutics. Genes (Basel) 2024, 15(7):903.

25. Evergren E, Mills IG, Kennedy G. Adaptations of membrane trafficking in cancer and tumorigenesis. J Cell Sci 2024, 137(10): jcs260943.

26. Smithgall MC, Yemelyanova A, Mathew S, Gogineni S; He B, Zhang T, et al. HER2/ERBB2 Immunohistochemical Expression and Copy Number Status in Ovarian Mucinous Tumors. International Journal of Gynecological Pathology 2024; 43(2): 134-39.

27. Kendall BM, Nemejcová K, Michálková R, Struzinská I, Hájková N, Hojný J, et al. HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma. Virchows Arch. 2023; 483(4): 497-507.

28. Yan M, Schwaederle M, Arguello D, Millis SZ, Gatalica Z, Kurzrock R. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 2015; 34(1): 157-64.

29. Wang Z. ErbB Receptors and Cancer. Methods Mol Biol. 2017; 1652:3-35.

30. Wang D, Zhu H, Ye Q, Wang C, Xu Y. Prognostic Value of KIF2A and HER2-Neu Overexpression in Patients With Epithelial Ovarian Cancer. Medicine (Baltimore) 2016; 95(8): e2803.